# Nadia Stefanova

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 117 papers | 5,480 citations | 116194 36 h-index | 104191 69 g-index |
| 123 all docs | 123 docs citations | 123 times ranked | 5770 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Host oligodendrogliopathy and Î±-synuclein strains dictate disease severity in multiple system atrophy. Brain, 2023, 146, 237-251. | 3.7 | 10 |
| 2 | The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy. Journal of Parkinson's Disease, 2022, 12, 105-115. | 1.5 | 9 |
| 3 | Spreading of Aggregated Î±-Synuclein in Sagittal Organotypic Mouse Brain Slices. Biomolecules, 2022, 12, 163. | 1.8 | 4 |
| 4 | Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?. Journal of Parkinson's Disease, 2022, 12, 1369-1387. | 1.5 | 10 |
| 5 | Microglia in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, S105-S112. | 1.5 | 18 |
| 6 | A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinsonâ€™s disease with dementia. Brain Communications, 2022, 4, . | 1.5 | 3 |
| 7 | Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. Movement Disorders, 2021, 36, 449-459. | 2.2 | 16 |
| 8 | Signs of early cellular dysfunction in multiple system atrophy. Neuropathology and Applied Neurobiology, 2021, 47, 268-282. | 1.8 | 16 |
| 9 | Multiple System Atrophy. , 2021, , 1-29. | | 0 |
| 10 | Neuropathology of multiple system atrophy: Kurt Jellinger`s legacy. Journal of Neural Transmission, 2021, 128, 1481-1494. | 1.4 | 6 |
| 11 | <scp>ATH434</scp> Reduces Î±â€Synucleinâ€Related Neurodegeneration in a Murine Model of Multiple System Atrophy. Movement Disorders, 2021, 36, 2605-2614. | 2.2 | 11 |
| 12 | Current experimental disease-modifying therapeutics for multiple system atrophy. Journal of Neural Transmission, 2021, 128, 1529-1543. | 1.4 | 11 |
| 13 | Is Multiple System Atrophy a Prion-like Disorder?. International Journal of Molecular Sciences, 2021, 22, 10093. | 1.8 | 12 |
| 14 | Toll-like receptor 4 deficiency facilitates Î±-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease. Parkinsonism and Related Disorders, 2021, 91, 59-65. | 1.1 | 12 |
| 15 | Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy. Neurobiology of Disease, 2021, 159, 105509. | 2.1 | 8 |
| 16 | The Concept of Î±-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders. Frontiers in Neurology, 2021, 12, 737195. | 1.1 | 12 |
| 17 | From Synaptic Protein to Prion: The Long and Controversial Journey of Î±-Synuclein. Frontiers in Synaptic Neuroscience, 2020, 12, 584536. | 1.3 | 20 |
| 18 | Histone Deacetylase 6 and the Disease Mechanisms of Î±-Synucleinopathies. Frontiers in Synaptic Neuroscience, 2020, 12, 586453. | 1.3 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Targeting Î±-synuclein by PD03 AFFITOPEÂ® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Translational Neurodegeneration, 2020, 9, 38. | 3.6 | 22 |
| 20 | Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in <scp>Î±â€Synucleinopathies</scp>. Movement Disorders, 2020, 35, 2333-2338. | 2.2 | 8 |
| 21 | Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. Acta Neuropathologica Communications, 2020, 8, 76. | 2.4 | 20 |
| 22 | Assessment of the Retina of Plp-Î±-Syn Mice as a Model for Studying Synuclein-Dependent Diseases. , 2020, 61, 12. | | 5 |
| 23 | Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy. Journal of Neural Transmission, 2020, 127, 205-212. | 1.4 | 6 |
| 24 | MSA: From basic mechanisms to experimental therapeutics. Parkinsonism and Related Disorders, 2020, 73, 94-104. | 1.1 | 13 |
| 25 | High-salt diet does not boost neuroinflammation and neurodegeneration in a model of Î±-synucleinopathy. Journal of Neuroinflammation, 2020, 17, 35. | 3.1 | 11 |
| 26 | Shock waves promote spinal cord repair via TLR3. JCI Insight, 2020, 5, . | 2.3 | 15 |
| 27 | The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent Î±-synuclein in experimental multiple system atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 165513. | 1.8 | 25 |
| 28 | Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies. Frontiers in Cellular Neuroscience, 2019, 13, 263. | 1.8 | 54 |
| 29 | Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice. Neurobiology of Disease, 2019, 125, 55-66. | 2.1 | 25 |
| 30 | Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. Clinical Autonomic Research, 2019, 29, 385-395. | 1.4 | 2 |
| 31 | L-dopa response pattern in a rat model of mild striatonigral degeneration. PLoS ONE, 2019, 14, e0218130. | 1.1 | 0 |
| 32 | Anle138b modulates Î±â€synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disorders, 2019, 34, 255-263. | 2.2 | 72 |
| 33 | The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. Journal of Alzheimer's Disease, 2018, 61, 1253-1273. | 1.2 | 47 |
| 34 | Progressive striatonigral degenerationÂin a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Acta Neuropathologica Communications, 2018, 6, 2. | 2.4 | 50 |
| 35 | Multiple system atrophy: experimental models and reality. Acta Neuropathologica, 2018, 135, 33-47. | 3.9 | 20 |
| 36 | Translational therapies for multiple system atrophy: Bottlenecks and future directions. Autonomic Neuroscience: Basic and Clinical, 2018, 211, 7-14. | 1.4 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82. | 1.5 | 23 |
| 38 | Region-Specific Effects of Immunotherapy With Antibodies Targeting Î±-synuclein in a Transgenic Model of Synucleinopathy. Frontiers in Neuroscience, 2018, 12, 452. | 1.4 | 31 |
| 39 | Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived Î±-synuclein in oligodendroglia: implications for MSA pathogenesis. BMC Neuroscience, 2018, 19, 32. | 0.8 | 11 |
| 40 | Very lateâ€onset pure autonomic failure. Movement Disorders, 2017, 32, 1106-1108. | 2.2 | 4 |
| 41 | Lower Affinity of Isradipine for L-Type Ca<sup>2+</sup> Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease. Journal of Neuroscience, 2017, 37, 6761-6777. | 1.7 | 72 |
| 42 | Distinct Parameters in the EEG of the PLP Î±-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity. Frontiers in Behavioral Neuroscience, 2017, 10, 252. | 1.0 | 14 |
| 43 | Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal Î±-synucleinopathy. Molecular Neurodegeneration, 2017, 12, 52. | 4.4 | 73 |
| 44 | Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. Frontiers in Neuroscience, 2016, 10, 99. | 1.4 | 23 |
| 45 | Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. PLoS ONE, 2016, 11, e0150705. | 1.1 | 26 |
| 46 | Preface. Movement Disorders, 2016, 31, 151-151. | 2.2 | 0 |
| 47 | Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. Movement Disorders, 2016, 31, 235-240. | 2.2 | 9 |
| 48 | Review: Multiple system atrophy: emerging targets for interventional therapies. Neuropathology and Applied Neurobiology, 2016, 42, 20-32. | 1.8 | 50 |
| 49 | Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Neurotherapeutics, 2016, 13, 871-879. | 2.1 | 17 |
| 50 | Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiology of Disease, 2016, 85, 262-274. | 2.1 | 156 |
| 51 | Overexpression of Î±-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. BMC Neuroscience, 2015, 16, 86. | 0.8 | 5 |
| 52 | Involvement of Peripheral Nerves in the Transgenic PLP-Î±-Syn Model of Multiple System Atrophy: Extending the Phenotype. PLoS ONE, 2015, 10, e0136575. | 1.1 | 17 |
| 53 | Animal models of multiple system atrophy. Clinical Autonomic Research, 2015, 25, 9-17. | 1.4 | 55 |
| 54 | Shock Wave Treatment Protects From Neuronal Degeneration via a Tollâ€Like Receptor 3 Dependent Mechanism: Implications of a Firstâ€Ever Causal Treatment for Ischemic Spinal Cord Injury. Journal of the American Heart Association, 2015, 4, e002440. | 1.6 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Enteric nervous system Î±-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology, 2015, 85, 1761-1768. | 1.5 | 121 |
| 56 | Alpha-synuclein immunoreactivity patterns in the enteric nervous system. Neuroscience Letters, 2015, 602, 145-149. | 1.0 | 40 |
| 57 | Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. Neurotoxicity Research, 2015, 28, 185-194. | 1.3 | 38 |
| 58 | Animal Models of Multiple-System Atrophy. , 2015, , 887-904. | | 0 |
| 59 | Multiple System Atrophy: Genetic or Epigenetic?. Experimental Neurobiology, 2014, 23, 277-291. | 0.7 | 28 |
| 60 | Towards translational therapies for multiple system atrophy. Progress in Neurobiology, 2014, 118, 19-35. | 2.8 | 35 |
| 61 | Multiple system atrophy as emerging template for accelerated drug discovery in Î±-synucleinopathies. Parkinsonism and Related Disorders, 2014, 20, 793-799. | 1.1 | 18 |
| 62 | The Role of Glia in Alpha-Synucleinopathies. Molecular Neurobiology, 2013, 47, 575-586. | 1.9 | 61 |
| 63 | Tollâ€like receptor 4 is required for Î±â€synuclein dependent activation of microglia and astroglia. Glia, 2013, 61, 349-360. | 2.5 | 542 |
| 64 | Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence. Experimental Neurology, 2013, 247, 531-536. | 2.0 | 46 |
| 65 | Models of Multiple System Atrophy. Current Topics in Behavioral Neurosciences, 2013, 22, 369-393. | 0.8 | 16 |
| 66 | Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Movement Disorders, 2013, 28, 347-355. | 2.2 | 50 |
| 67 | Intact Olfaction in a Mouse Model of Multiple System Atrophy. PLoS ONE, 2013, 8, e64625. | 1.1 | 20 |
| 68 | CaV1.2 Calcium Channel Expression in Reactive Astrocytes is associated with the Formation of Amyloid-Î² Plaques in an Alzheimer's Disease Mouse Model. Journal of Alzheimer's Disease, 2013, 37, 439-451. | 1.2 | 39 |
| 69 | Cell Fate Analysis of Embryonic Ventral Mesencephalic Grafts in the 6-OHDA Model of Parkinson's Disease. PLoS ONE, 2012, 7, e50178. | 1.1 | 1 |
| 70 | Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human Î±-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathologica, 2012, 124, 51-65. | 3.9 | 73 |
| 71 | Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. Neurotoxicity Research, 2012, 21, 393-404. | 1.3 | 96 |
| 72 | Kappa opioid receptor activation blocks progressive neurodegeneration after kainic acid injection. Hippocampus, 2011, 21, 1010-1020. | 0.9 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Toll-Like Receptor 4 Promotes Î±-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons. American Journal of Pathology, 2011, 179, 954-963. | 1.9 | 230 |
| 74 | Glial dysfunction in the pathogenesis of Î±-synucleinopathies: emerging concepts. Acta Neuropathologica, 2011, 121, 675-693. | 3.9 | 164 |
| 75 | Nogo-B is associated with cytoskeletal structures in human monocyte-derived macrophages. BMC Research Notes, 2011, 4, 6. | 0.6 | 20 |
| 76 | Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Movement Disorders, 2011, 26, 507-515. | 2.2 | 17 |
| 77 | Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection. PLoS ONE, 2011, 6, e19808. | 1.1 | 77 |
| 78 | Etiology, Pathology, and Pathogenesis. Blue Books of Neurology, 2010, 34, 321-339. | 0.1 | 2 |
| 79 | Targeted overexpression of human Î±-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure. Experimental Neurology, 2010, 224, 459-464. | 2.0 | 65 |
| 80 | Multiple System Atrophy: Animal Models. , 2010, , 229-232. | | 0 |
| 81 | Multiple system atrophy: an update. Lancet Neurology, The, 2009, 8, 1172-1178. | 4.9 | 406 |
| 82 | Striatal transplantation in a rodent model of multiple system atrophy: Effects on Lâ€Dopa response. Journal of Neuroscience Research, 2009, 87, 1679-1685. | 1.3 | 23 |
| 83 | Mitochondrial inhibitor 3â€nitroproprionic acid enhances oxidative modification of alphaâ€synuclein in a transgenic mouse model of multiple system atrophy. Journal of Neuroscience Research, 2009, 87, 2728-2739. | 1.3 | 78 |
| 84 | Recent developments in multiple system atrophy. Journal of Neurology, 2009, 256, 1791-1808. | 1.8 | 86 |
| 85 | Striatal transplantation for multiple system atrophy â€" Are grafts affected by Î±-synucleinopathy?. Experimental Neurology, 2009, 219, 368-371. | 2.0 | 28 |
| 86 | Multiple system atrophy: A primary oligodendrogliopathy. Annals of Neurology, 2008, 64, 239-246. | 2.8 | 279 |
| 87 | Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Experimental Neurology, 2008, 210, 421-427. | 2.0 | 79 |
| 88 | Axl and Growth Arrestâ€"Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme. Clinical Cancer Research, 2008, 14, 130-138. | 3.2 | 240 |
| 89 | Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. Movement Disorders, 2007, 22, 353-358. | 2.2 | 13 |
| 90 | Microglial activation mediates neurodegeneration related to oligodendroglial Î±â€synucleinopathy: Implications for multiple system atrophy. Movement Disorders, 2007, 22, 2196-2203. | 2.2 | 203 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence. Movement Disorders, 2007, 22, 969-973. | 2.2 | 6 |
| 92 | Animal models of multiple system atrophy. Trends in Neurosciences, 2005, 28, 501-506. | 4.2 | 77 |
| 93 | In vitro models of multiple system atrophy. Movement Disorders, 2005, 20, S53-S56. | 2.2 | 22 |
| 94 | Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 3.9 | 9 |
| 95 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). Journal of Neural Transmission, 2005, 112, 1025-1033. | 1.4 | 34 |
| 96 | Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. NeuroImage, 2005, 24, 822-831. | 2.1 | 24 |
| 97 | Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. Brain Research Bulletin, 2005, 68, 54-58. | 1.4 | 11 |
| 98 | Oxidative Stress in Transgenic Mice with Oligodendroglial Î±-Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy. American Journal of Pathology, 2005, 166, 869-876. | 1.9 | 191 |
| 99 | Double-Lesion Animal Models of Multiple System Atrophy. , 2005, , 571-583. | | 0 |
| 100 | Neuroprotective agents for clinical trials in Parkinsonâ€™s disease: A systematic assessment. Neurology, 2004, 62, 158-159. | 1.5 | 18 |
| 101 | Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. Journal of Neuroscience Research, 2004, 78, 87-91. | 1.3 | 28 |
| 102 | Effects of pulsatile l-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiology of Disease, 2004, 15, 630-639. | 2.1 | 28 |
| 103 | Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system) Tj ETQq1 1 0.784314 rgBT /Overlock 10 | 4.8 | 82 |
| 104 | Tumor necrosis factor-?-induced cell death in U373 cells overexpressing ?-synuclein. Journal of Neuroscience Research, 2003, 73, 334-340. | 1.3 | 37 |
| 105 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. Neuroscience Letters, 2002, 335, 34-38. | 1.0 | 33 |
| 106 | Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience, 2002, 114, 1005-1017. | 1.1 | 147 |
| 107 | Ultrastructure of Î±-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells. Neuroscience Letters, 2002, 323, 37-40. | 1.0 | 19 |
| 108 | Freezing of gait in postmortem-confirmed atypical parkinsonism. Movement Disorders, 2002, 17, 1041-1045. | 2.2 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Glial cell death induced by overexpression of ?-synuclein. Journal of Neuroscience Research, 2001, 65, 432-438. | 1.3 | 87 |
| 110 | Overstimulation of the Î±1B-adrenergic receptor causes a â€œseizure plusâ€•syndrome. Nature Medicine, 2001, 7, 132-132. | 15.2 | 5 |
| 111 | Multiple System Atrophy. Seminars in Neurology, 2001, 21, 033-040. | 0.5 | 17 |
| 112 | Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy). Experimental Neurology, 2000, 164, 166-175. | 2.0 | 16 |
| 113 | Sexual Dimorphism of the Bed Nucleus of the Stria Terminalis and the Amygdala. Advances in Anatomy, Embryology and Cell Biology, 2000, 158, III-X, 1-78. | 1.0 | 22 |
| 114 | Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment. , 2000, , 335-343. | | 22 |
| 115 | Î³-Aminobutyric acid-immunoreactive neurons in the amygdala of the rat â€“ sex differences and effect of early postnatal castration. Neuroscience Letters, 1998, 255, 175-177. | 1.0 | 27 |
| 116 | Sex and age differences of neurons expressing gaba-immunoreactivity in the rat bed nucleus of the stria terminalis. International Journal of Developmental Neuroscience, 1998, 16, 443-448. | 0.7 | 12 |
| 117 | Distribution of GABA-immunoreactive nerve cells in the bed nucleus of the stria terminalis in male and female rats. European Journal of Histochemistry, 1997, 41, 23-8. | 0.6 | 17 |